C117307
Bromocyclopropane
99%
Synonyme(s) :
Cyclopropyl bromide
Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
Changer de vue
A propos de cet article
Formule empirique (notation de Hill) :
C3H5Br
Numéro CAS:
Poids moléculaire :
120.98
UNSPSC Code:
12352100
NACRES:
NA.22
PubChem Substance ID:
EC Number:
224-375-7
Beilstein/REAXYS Number:
1900287
MDL number:
Assay:
99%
Form:
liquid
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderQuality Level
assay
99%
form
liquid
refractive index
n20/D 1.458 (lit.)
bp
69 °C (lit.)
density
1.51 g/mL at 25 °C (lit.)
storage temp.
2-8°C
SMILES string
BrC1CC1
InChI
1S/C3H5Br/c4-3-1-2-3/h3H,1-2H2
InChI key
LKXYJYDRLBPHRS-UHFFFAOYSA-N
General description
Bromocyclopropane acts as a key intermediate in organic synthesis and a building block for constructing diverse chemical structures in drug development.
signalword
Danger
hcodes
Hazard Classifications
Flam. Liq. 2
Classe de stockage
3 - Flammable liquids
wgk
WGK 3
flash_point_f
21.2 °F - closed cup
flash_point_c
-6 °C - closed cup
ppe
Eyeshields, Faceshields, Gloves, type ABEK (EN14387) respirator filter
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Mechanism-Driven Elaboration of an Enantioselective Bromocyclopropanation Reaction of Allylic Alcohols
S Taillemaud, et al.
Angewandte Chemie (International Edition in English), 127, 14314-14318 (2015)
John R Hornick et al.
Journal of experimental & clinical cancer research : CR, 31, 41-41 (2012-05-04)
Sigma-2 receptor ligands have been studied for treatment of pancreatic cancer because they are preferentially internalized by proliferating cells and induce apoptosis. This mechanism of apoptosis is poorly understood, with varying reports of caspase-3 dependence. We evaluated multiple sigma-2 receptor
Carmen Abate et al.
ChemMedChem, 6(1), 73-80 (2010-11-12)
Many new chemotherapeutic agents are under preclinical investigation and, despite efforts to more selectively target cancer cells, limitations such as toxicity and inherent resistance are often encountered. Therefore, alternative strategies are needed to treat cancer and overcome such limitations. We